Overactive Bladder Treatment Market Segmentation:
Patient Age Group Segment Analysis
The patient age group segment is expected to be dominated by adults (≥18 years), with almost 85% of the market share by 2035. According to a report of NLM, March 2024, the adult patient age group segment includes patients aged 18 and above who require treatment for OAB with medications such as mirabegron or antimuscarinics. This segment is significant as it constitutes the biggest and most researched population being treated with OAB therapies. The switch and persistence pattern of treatment in adult patients has become an area of interest for manufacturers and healthcare organizations, creating demand for the market and further growth.
Disease Type Segment Analysis
The disease type segment is expected to be dominated by idiopathic overactive bladder. The idiopathic overactive bladder is driven by its huge prevalence and patient load. According to the 2024 American Urological Association clinical guideline, the treatment is individualized rather than given through a stepwise approach to any patient. As per an NLM July 2023 report, research shows that 70% to 84% of patients with spinal cord injuries have neurogenic bladder dysfunction at some point in their lives. The focus is on shared decision-making, where practitioners can select treatments based on the patient's wants, ranging from behavioral interventions, medication, and minimally invasive options.
Route of Administration Segment Analysis
The route of administration segment is expected to be dominated by oral within the forecast period. The oral routes are associated with certain advantages, such as easy administration, high patient compliance, and convenience, in contrast to invasive procedures. This sub-segment thrives mainly because patients and clinicians prefer to manage OAB symptoms efficiently with the well-established oral forms of antimuscarinics and β3 agonists. Moreover, the persistent improvements in the oral formulations of drugs are not just increasing their efficacy but also diminishing their side effects, which is further influencing the inclination of the market.
Our in-depth analysis of the overactive bladder treatment market includes the following segments:
|
Segment |
Sub-segments |
|
Therapy / Drug Class |
|
|
Disease Type |
|
|
Route of Administration |
|
|
Distribution Channel |
|
|
Patient Age Group |
|
|
End User |
|
